Hepatitis B Virus News and Research

RSS

Occurrence of advanced liver fibrosis similar for patients with HCV infection

Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.

25 Apr 2015

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.

25 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Results announced today at The International Liver Congress 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer.

25 Apr 2015

Study highlights need to increase current levels of interventions to reduce HBV transmission

Results revealed today at The International Liver Congress 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible.

23 Apr 2015

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.

23 Apr 2015

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high sustained virologic response rates 12 weeks post treatment (SVR12) in patients with chronic hepatitis C virus (HCV) infection who have decompensated liver disease (cirrhosis) or have undergone liver transplantation.

23 Apr 2015

Novel immunotherapeutic shows promise against chronic hepatitis B

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress 2015.

23 Apr 2015

Civacir can effectively prevent HCV recurrence following liver transplants

New data from an ongoing Phase III trial revealed today at The International Liver Congress 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT).

23 Apr 2015

Study reveals impact of delaying HCV treatment

Data revealed today at The International Liver Congress 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on treatment efficacy, increasing the risk of morbidity and mortality among patients.

23 Apr 2015

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Researchers from Taiwan determined that individuals with human immunodeficiency virus (HIV) infection or those who inject illicit drugs have a higher risk of becoming infected with the hepatitis D virus (HDV) in that country.

22 Apr 2015

Bio-Rad grants Beckman Coulter exclusive distribution rights for access HIV and Hepatitis C assays

Bio-Rad is extending its agreement with Beckman Coulter and has named the company exclusive global distributor of Bio-Rad’s Access HIV combo assay and the Access hepatitis C virus (HCV) assay in select geographies...

From Beckman Coulter Diagnostics 21 Apr 2015

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

AbbVie today announced that the Japanese Ministry of Health, Labour and Welfare has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir.

16 Apr 2015

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Research suggests that virological, serological and histological outcomes are comparable between cirrhotic and noncirrhotic patients with chronic hepatitis B virus infection undergoing long-term tenofovir disoproxil fumarate treatment.

13 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

New HCV therapies cost-effective in specific groups of HCV-infected patients

A study led by Boston Medical Center researchers demonstrates that while new therapies to treat Hepatitis C Virus (HCV) are highly effective, they are cost-effective and provide the greatest value in specific groups of HCV-infected patients.

31 Mar 2015

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B.

26 Mar 2015

New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness analysis led by researchers at The University of Texas MD Anderson Cancer Center.

17 Mar 2015

Long-term entecavir, TDF effective in chronic HBV in real-world setting

A Turkish clinical practice study shows that entecavir and tenofovir disoproxil fumarate can effectively maintain long-term virological and biochemical responses in patients with chronic hepatitis B virus infection, both in those with and without cirrhosis.

13 Mar 2015

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Hepatitis B surface antigen and hepatitis B core-related antigen levels can predict long-term response to sequential nucleos(t)ide analogue and interferon-α therapy in patients with chronic hepatitis B virus infection, research indicates.

13 Mar 2015

Hepatitis B Virus News and Research

Occurrence of advanced liver fibrosis similar for patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Study highlights need to increase current levels of interventions to reduce HBV transmission

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Novel immunotherapeutic shows promise against chronic hepatitis B

Civacir can effectively prevent HCV recurrence following liver transplants

Study reveals impact of delaying HCV treatment

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Bio-Rad grants Beckman Coulter exclusive distribution rights for access HIV and Hepatitis C assays

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

No effect of baseline cirrhosis on long-term TDF treatment outcomes

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New HCV therapies cost-effective in specific groups of HCV-infected patients

Study: HBV exposure increases immune system maturation of infants

New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

Long-term entecavir, TDF effective in chronic HBV in real-world setting

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News